Finance

Lists
Why is ACRS down ၂.၇၃%?
Dive Deeper
ACRS:NASDAQ
Aclaris Therapeutics Inc
၄.၂၇ US$
-၂.၇၃%
(-၀.၁၂) 1D
၄.၂၇ US$
၀.၀၀% (၀.၀၀)
After hours
Closed: အောက် ၅, GMT-၄ ၁၆:၀၀:၀၁  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ACRS...
Open
၄.၃၄ US$
High
၄.၄၁ US$
Low
၄.၀၆ US$
Mkt. cap
၆၂.၈၅ ကုဋေ
Avg. vol.
၂.၇၀ သန်း
Volume
၀.၀၀
52-wk high
၆.၆၀ US$
52-wk low
၁.၇၄ US$
EPS
-၀.၅၉ US$
Beta
၀.၈၇
Shares outstanding
၁၄.၇၂ ကုဋေ
No. of employees
၇၁
Open
၄.၃၄ US$
High
၄.၄၁ US$
Low
၄.၀၆ US$
Mkt. cap
၆၂.၈၅ ကုဋေ
Avg. vol.
၂.၇၀ သန်း
Volume
၀.၀၀
52-wk high
၆.၆၀ US$
52-wk low
၁.၇၄ US$
EPS
-၀.၅၉ US$
Beta
၀.၈၇
Shares outstanding
၁၄.၇၂ ကုဋေ
No. of employees
၇၁
News stories
From web sources and news partners
Simply Wall Street
Simply Wall Street
·
ပြီးခဲ့သည့် ၁၇ မိနစ်
Novavax (NVAX) Stock Looks Fully Priced On Its Current Sales Base
Seeking Alpha
Seeking Alpha
·
ပြီးခဲ့သည့် ၃၆ မိနစ်
2 Tickets To Outperformance
WXXV News 25
WXXV News 25
·
ပြီးခဲ့သည့် ၁ နာရီ
US stocks rise to the edge of an all-time high
About Aclaris Therapeutics Inc
CEO-
Employees၇၁
Founded၂၀၁၂
Headquarters-
Sector-
Analyst ratings
Based on 5 analysts giving stock ratings to ACRS in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for ACRS in the last 3 months.
Highest
Current ၄.၂၇ US$
၁၆.၀၀ US$ (+၂၇၄.၇၁%)
Average
၁၂.၀၀ US$ (+၁၈၁.၀၃%)
Lowest
၁၀.၀၀ US$ (+၁၃၄.၁၉%)
Analyst
Recommendation
Action
Price target
Projected
Date
Kate Dellorusso
LifeSci Capital
Buy
Maintained
၁၃.၀၀ US$
+၂၀၄.၄%
10/01/2026
Edward Nash
Canaccord Genuity
Buy
Initiated
၁၀.၀၀ US$
+၁၃၄.၂%
09/01/2026
Biren Amin
Piper Sandler
Buy
Maintained
၁၁.၀၀ US$
+၁၅၇.၆%
08/31/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
၁၆.၀၀ US$
+၂၇၄.၇%
08/10/2026
Adam Vogel
Craig-Hallum
Buy
Maintained
၁၀.၀၀ US$
+၁၃၄.၂%
08/06/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
၁၂.၀၀ US$
+၁၈၁%
05/11/2026
Martin Fan
Wedbush
Buy
Maintained
၁၀.၀၀ US$
+၁၃၄.၂%
05/08/2026
Jeff Jones
Oppenheimer
Buy
Reiterated
၁၀.၀၀ US$
+၁၃၄.၂%
05/08/2026
Alex Thompson CFA
Stifel Nicolaus
Hold
Maintained
၄.၀၀ US$
-၆.၃%
05/08/2026
Unknown Analyst
Goldman Sachs
Buy
Maintained
၁၀.၀၀ US$
+၁၃၄.၂%
04/16/2026
Last report
၂၀၂၆ ဩ ၆
Fiscal period
Q2 2026
EPS / Est. (USD)
-၀.၁၅ US$ / -၀.၁၆ US$
+၄.၅၄%beat
Revenue / Est. (USD)
၁.၆၃ သန်း / ၁.၅၄ သန်း
+၆.၁၁%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
၃.၃၀ သန်း
၁.၃၀ သန်း
၂.၀၀ သန်း
၁.၆၃ သန်း
Cost of goods sold
၁.၅၅ ကုဋေ
၁.၈၁ ကုဋေ
၁.၇၄ ကုဋေ
၁.၉၅ ကုဋေ
Cost of revenue
၁.၅၅ ကုဋေ
၁.၈၁ ကုဋေ
၁.၇၄ ကုဋေ
၁.၉၅ ကုဋေ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၄.၈၇ သန်း
၅.၅၈ သန်း
၆.၇၄ သန်း
၆.၀၅ သန်း
Operating expense
၄.၈၇ သန်း
၅.၅၈ သန်း
၆.၇၄ သန်း
၆.၀၅ သန်း
Total operating expenses
၂.၀၃ ကုဋေ
၂.၃၆ ကုဋေ
၂.၄၂ ကုဋေ
၂.၅၆ ကုဋေ
Operating income
-၁.၇၀ ကုဋေ
-၂.၂၃ ကုဋေ
-၂.၂၂ ကုဋေ
-၂.၃၉ ကုဋေ
Other non operating income
၇.၁၆ သိန်း
၁.၃၀ သန်း
၈.၅၄ သိန်း
၉.၇၂ သိန်း
EBT including unusual items
-၁.၄၆ ကုဋေ
-၁.၉၈ ကုဋေ
-၁.၉၈ ကုဋေ
-၂.၁၅ ကုဋေ
EBT excluding unusual items
-၁.၄၅ ကုဋေ
-၁.၉၄ ကုဋေ
-၁.၉၈ ကုဋေ
-၂.၁၂ ကုဋေ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-၁.၄၆ ကုဋေ
-၁.၉၈ ကုဋေ
-၁.၉၈ ကုဋေ
-၂.၁၅ ကုဋေ
Net profit margin
-၄၄၂.၉၈%
-၁,၅၂၈.၅၇%
-၉၉၃.၁၉%
-၁,၃၂၀.၁၃%
Earnings per share
-၀.၁၂
-၀.၁၆
-၀.၁၅
-၀.၁၅
Interest and investment income
၁.၈၂ သန်း
၁.၆၃ သန်း
၁.၅၁ သန်း
၁.၇၆ သန်း
Interest expense
-
-
-
-
Net interest expenses
၁.၈၂ သန်း
၁.၆၃ သန်း
၁.၅၁ သန်း
၁.၇၆ သန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၁.၇၀ ကုဋေ
-၂.၂၃ ကုဋေ
-၂.၂၂ ကုဋေ
-၂.၃၉ ကုဋေ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google အက်ပ်များ